Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Trastuzumab Rezetecan

  • Home
  • Trastuzumab Rezetecan
Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels
Posted innews Oncology Otorhinolaryngology

Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels

Posted by MedXY By MedXY 08/14/2026
This phase II trial demonstrates significant antitumor activity of trastuzumab rezetecan in both HER2-high and HER2-low advanced salivary gland carcinoma with a manageable safety profile, offering new hope for this challenging malignancy.
Read More
  • Extra-Endocrine Features in Infancy as Early Clues to Multiple Endocrine Neoplasia Type 2B: A Case Series from Bambino Gesù Children’s Hospital
  • Agency-Level Variability in Futility Determinations and Termination of Resuscitation for Pediatric Out-of-Hospital Cardiac Arrest
  • Early Exclusive Enteral Feeding in Preterm Infants: Assessing Safety and Benefits through Meta-Analysis
  • Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: Key Recommendations from the ASCO Living Guideline (Version 2026.1.4)
  • Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in